APO RESEARCH · REPORT
Induced Pluripotent Stem Cells (iPSCs)
Induced pluripotent stem cells (also known as iPS cells or iPSCs) are a type of pluripotent stem cell that can be generated directly from adult cells. The opportunities concerning a wide range of diseases including neurodegenerative, metabolic and cardiovascular diseases in a dish for cheaper and faster drug discovery. This may be particularly important in the context of monogenic rare hereditary diseases, where iPSCs can provide an alternative model system to compensate for the lack of a predictive in-vitro human model for drug discovery.
Product & engineering
Understand the product.
Induced pluripotent stem cells (also known as iPS cells or iPSCs) are a type of pluripotent stem cell that can be generated directly from adult cells. The opportunities concerning a wide range of diseases including neurodegenerative, metabolic and cardiovascular diseases in a dish for cheaper and faster drug discovery. This may be particularly important in the context of monogenic rare hereditary diseases, where iPSCs can provide an alternative model system to compensate for the lack of a predictive in-vitro human model for drug discovery.
Selected research
Industry Research
Induced Pluripotent Stem Cells (iPSCs) Industry Research Report 2026
Market perspective
Induced pluripotent stem cells (also known as iPS cells or iPSCs) are a type of pluripotent stem cell that can be generated directly from adult cells. The opportunities concerning a wide range of diseases including neurodegenerative, metabolic and cardiovascular diseases in a dish for cheaper and faster drug discovery. This may be particularly important in the context of monogenic rare hereditary diseases, where iPSCs can provide an alternative model system to compensate for the lack of a predictive in-vitro human model for drug discovery.
United States is the largest Induced Pluripotent Stem Cells (iPSCs) market with about 43% market share. Europe is follower, accounting for about 33% market share.
The key players are Fujifilm Holding Corporation (CDI), Ncardia, Sumitomo Dainippon Pharma, Astellas Pharma Inc, Fate Therapeutics, Inc, Pluricell Biotech, Cell Inspire Biotechnology, ReproCELL etc. Top 3 companies occupied about 73% market share.
Read the full market overview
Report Scope
This report quantifies the global Induced Pluripotent Stem Cells (iPSCs) market in terms of revenue (US$ million) and, where applicable, service volume (), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Induced Pluripotent Stem Cells (iPSCs).
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Induced Pluripotent Stem Cells (iPSCs) Market by Company
Fujifilm Holding Corporation (CDI)
Ncardia
Sumitomo Dainippon Pharma
Astellas Pharma Inc
Fate Therapeutics, Inc
Pluricell Biotech
Cell Inspire Biotechnology
ReproCELL
Induced Pluripotent Stem Cells (iPSCs) Segment by Type
Human iPSCs
Mouse iPSCs
Induced Pluripotent Stem Cells (iPSCs) Segment by Application
Academic Research
Drug Development and Discovery
Toxicity Screening
Regenerative Medicine
Others
Induced Pluripotent Stem Cells (iPSCs) Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Induced Pluripotent Stem Cells (iPSCs) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Induced Pluripotent Stem Cells (iPSCs) and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Induced Pluripotent Stem Cells (iPSCs).
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Induced Pluripotent Stem Cells (iPSCs) companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Human iPSCs
- Mouse iPSCs
Applications
- Academic Research
- Drug Development and Discovery
- Toxicity Screening
- Regenerative Medicine
- Others
Companies covered
- Fujifilm Holding Corporation (CDI)
- Ncardia
- Sumitomo Dainippon Pharma
- Astellas Pharma Inc
- Fate Therapeutics, Inc
- Pluricell Biotech
- Cell Inspire Biotechnology
- ReproCELL
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Induced Pluripotent Stem Cells (iPSCs) by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Human iPSCs
- 2.2.3 Mouse iPSCs
- 2.3 Induced Pluripotent Stem Cells (iPSCs) by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Academic Research
- 2.3.3 Drug Development and Discovery
- 2.3.4 Toxicity Screening
- 2.3.5 Regenerative Medicine
- 2.3.6 Others
- 2.4 Assumptions and Limitations
3 Induced Pluripotent Stem Cells (iPSCs) Breakdown Data by Type
- 3.1 Global Induced Pluripotent Stem Cells (iPSCs) Historic Market Size by Type (2021-2026)
- 3.2 Global Induced Pluripotent Stem Cells (iPSCs) Forecasted Market Size by Type (2027-2032)
4 Induced Pluripotent Stem Cells (iPSCs) Breakdown Data by Application
- 4.1 Global Induced Pluripotent Stem Cells (iPSCs) Historic Market Size by Application (2021-2026)
- 4.2 Global Induced Pluripotent Stem Cells (iPSCs) Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Induced Pluripotent Stem Cells (iPSCs) Market Perspective (2021-2032)
- 5.2 Global Induced Pluripotent Stem Cells (iPSCs) Growth Trends by Region
- 5.2.1 Global Induced Pluripotent Stem Cells (iPSCs) Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Induced Pluripotent Stem Cells (iPSCs) Historic Market Size by Region (2021-2026)
- 5.2.3 Induced Pluripotent Stem Cells (iPSCs) Forecasted Market Size by Region (2027-2032)
- 5.3 Induced Pluripotent Stem Cells (iPSCs) Market Dynamics
- 5.3.1 Induced Pluripotent Stem Cells (iPSCs) Industry Trends
- 5.3.2 Induced Pluripotent Stem Cells (iPSCs) Market Drivers
- 5.3.3 Induced Pluripotent Stem Cells (iPSCs) Market Challenges
- 5.3.4 Induced Pluripotent Stem Cells (iPSCs) Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Induced Pluripotent Stem Cells (iPSCs) Players by Revenue
- 6.1.1 Global Top Induced Pluripotent Stem Cells (iPSCs) Players by Revenue (2021-2026)
- 6.1.2 Global Induced Pluripotent Stem Cells (iPSCs) Revenue Market Share by Players (2021-2026)
- 6.2 Global Induced Pluripotent Stem Cells (iPSCs) Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Induced Pluripotent Stem Cells (iPSCs) Head Office and Area Served
- 6.4 Global Induced Pluripotent Stem Cells (iPSCs) Players, Product Type & Application
- 6.5 Global Induced Pluripotent Stem Cells (iPSCs) Manufacturers Established Date
- 6.6 Global Induced Pluripotent Stem Cells (iPSCs) Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Induced Pluripotent Stem Cells (iPSCs) Market Size (2021-2032)
- 7.2 North America Induced Pluripotent Stem Cells (iPSCs) Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Induced Pluripotent Stem Cells (iPSCs) Market Size by Country (2021-2026)
- 7.4 North America Induced Pluripotent Stem Cells (iPSCs) Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Induced Pluripotent Stem Cells (iPSCs) Market Size (2021-2032)
- 8.2 Europe Induced Pluripotent Stem Cells (iPSCs) Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Induced Pluripotent Stem Cells (iPSCs) Market Size by Country (2021-2026)
- 8.4 Europe Induced Pluripotent Stem Cells (iPSCs) Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Induced Pluripotent Stem Cells (iPSCs) Market Size (2021-2032)
- 9.2 Asia-Pacific Induced Pluripotent Stem Cells (iPSCs) Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Induced Pluripotent Stem Cells (iPSCs) Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Induced Pluripotent Stem Cells (iPSCs) Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Induced Pluripotent Stem Cells (iPSCs) Market Size (2021-2032)
- 10.2 South America Induced Pluripotent Stem Cells (iPSCs) Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Induced Pluripotent Stem Cells (iPSCs) Market Size by Country (2021-2026)
- 10.4 South America Induced Pluripotent Stem Cells (iPSCs) Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Induced Pluripotent Stem Cells (iPSCs) Market Size (2021-2032)
- 11.2 Middle East & Africa Induced Pluripotent Stem Cells (iPSCs) Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Induced Pluripotent Stem Cells (iPSCs) Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Induced Pluripotent Stem Cells (iPSCs) Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Fujifilm Holding Corporation (CDI)
- 12.1.1 Fujifilm Holding Corporation (CDI) Company Information
- 12.1.2 Fujifilm Holding Corporation (CDI) Business Overview
- 12.1.3 Fujifilm Holding Corporation (CDI) Revenue in Induced Pluripotent Stem Cells (iPSCs) Business (2021-2026)
- 12.1.4 Fujifilm Holding Corporation (CDI) Induced Pluripotent Stem Cells (iPSCs) Product Portfolio
- 12.1.5 Fujifilm Holding Corporation (CDI) Recent Developments
- 12.2 Ncardia
- 12.2.1 Ncardia Company Information
- 12.2.2 Ncardia Business Overview
- 12.2.3 Ncardia Revenue in Induced Pluripotent Stem Cells (iPSCs) Business (2021-2026)
- 12.2.4 Ncardia Induced Pluripotent Stem Cells (iPSCs) Product Portfolio
- 12.2.5 Ncardia Recent Developments
- 12.3 Sumitomo Dainippon Pharma
- 12.3.1 Sumitomo Dainippon Pharma Company Information
- 12.3.2 Sumitomo Dainippon Pharma Business Overview
- 12.3.3 Sumitomo Dainippon Pharma Revenue in Induced Pluripotent Stem Cells (iPSCs) Business (2021-2026)
- 12.3.4 Sumitomo Dainippon Pharma Induced Pluripotent Stem Cells (iPSCs) Product Portfolio
- 12.3.5 Sumitomo Dainippon Pharma Recent Developments
- 12.4 Astellas Pharma Inc
- 12.4.1 Astellas Pharma Inc Company Information
- 12.4.2 Astellas Pharma Inc Business Overview
- 12.4.3 Astellas Pharma Inc Revenue in Induced Pluripotent Stem Cells (iPSCs) Business (2021-2026)
- 12.4.4 Astellas Pharma Inc Induced Pluripotent Stem Cells (iPSCs) Product Portfolio
- 12.4.5 Astellas Pharma Inc Recent Developments
- 12.5 Fate Therapeutics, Inc
- 12.5.1 Fate Therapeutics, Inc Company Information
- 12.5.2 Fate Therapeutics, Inc Business Overview
- 12.5.3 Fate Therapeutics, Inc Revenue in Induced Pluripotent Stem Cells (iPSCs) Business (2021-2026)
- 12.5.4 Fate Therapeutics, Inc Induced Pluripotent Stem Cells (iPSCs) Product Portfolio
- 12.5.5 Fate Therapeutics, Inc Recent Developments
- 12.6 Pluricell Biotech
- 12.6.1 Pluricell Biotech Company Information
- 12.6.2 Pluricell Biotech Business Overview
- 12.6.3 Pluricell Biotech Revenue in Induced Pluripotent Stem Cells (iPSCs) Business (2021-2026)
- 12.6.4 Pluricell Biotech Induced Pluripotent Stem Cells (iPSCs) Product Portfolio
- 12.6.5 Pluricell Biotech Recent Developments
- 12.7 Cell Inspire Biotechnology
- 12.7.1 Cell Inspire Biotechnology Company Information
- 12.7.2 Cell Inspire Biotechnology Business Overview
- 12.7.3 Cell Inspire Biotechnology Revenue in Induced Pluripotent Stem Cells (iPSCs) Business (2021-2026)
- 12.7.4 Cell Inspire Biotechnology Induced Pluripotent Stem Cells (iPSCs) Product Portfolio
- 12.7.5 Cell Inspire Biotechnology Recent Developments
- 12.8 ReproCELL
- 12.8.1 ReproCELL Company Information
- 12.8.2 ReproCELL Business Overview
- 12.8.3 ReproCELL Revenue in Induced Pluripotent Stem Cells (iPSCs) Business (2021-2026)
- 12.8.4 ReproCELL Induced Pluripotent Stem Cells (iPSCs) Product Portfolio
- 12.8.5 ReproCELL Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst